Abacavir: its use and hypersensitivity
AbstractAbacavir, a nucleoside reverse transcriptase inhibitor, is useful in first- and second-line HIV therapy and as a substitute for stavudine and zidovudine when toxicity is a problem. Although it is safe and well tolerated, a lifethreatening hypersensitivity reaction can occur. The risk for developing this reaction relates to the presence of specific genotypes, especially HLA-B*5701.
The author(s) retain copyright on work published by AOSIS unless specified otherwise.
Licensing and publishing rights
Author(s) of work published by AOSIS are required to grant AOSIS the unlimited rights to publish the definitive work in any format, language and medium, for any lawful purpose. AOSIS requires journal authors to publish their work in open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
Read more here: http://creativecommons.org/licenses/by/4.0/.
The authors retain the non-exclusive right to do anything they wish with the published article(s), provided attribution is given to the applicable journal with details of the original publication, as set out in the official citation of the article published in the journal. The retained right specifically includes the right to post the article on the authors’ or their institution’s websites or in institutional repositories.
Previously published work may have been published under a different licence. We advise the community that if they would like to reuse the work to consult the applicable licence at article level.